Zydus completes enrollment in three phase III Saroglitazar trials to treat NASH
Zydus Cadila announced that it has completed enrollment in EVIDENCES II, EVIDENCES III and EVIDENCES V phase 3 clinical trials of Saroglitazar mg for treating Non-Alcoholic SteatoHepatitis (NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.
Pankaj R. Patel, chairman, Zydus Group said, “We are excited about the progress that Saroglitazar mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients. NASH is an area of unmet healthcare need and we are committed to develop this therapy for millions of patients suffering from this deadly disease.”